2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial

Emiel A De Jaeghere; Sandra Tuyaerts; An MT van Nuffel; Ann Belmans; Kris Bogaerts; Regina Baiden-Amissah; Peter Vuylsteke; Stéphanie Henry; Xuan Bich Trinh; Peter A van Dam; Sandrine Aspeslagh; Alex de Caluwé; Eline Naert; Diether Lambrechts; An Hendrix; Olivier de Wever; Koen K van de Vijver; Frédéric Amant; Katrien Vandecasteele; Hannelore G Denys

doi:10.1136/ijgc-2022-ESGO.401

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article metrics

Miscellaneous

2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial

Free

	Abstract	Pdf
Oct 2022	18	4
Nov 2022	45	9
Dec 2022	73	14
Jan 2023	47	8
Feb 2023	29	3
Mar 2023	11	0
Total	223	38

Main menu

Online download statistics by month:

Online download statistics by month: October 2022 to March 2023

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month: October 2022 to March 2023

Read the full text or download the PDF:

Log in using your username and password